Opinion|Videos|September 18, 2024
Type 2 Inflammatory Diseases and Impact on Quality of Life
Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and limitations in daily activities.
Advertisement
Episodes in this series
- How do type 2 inflammatory diseases, such as asthma, eosinophilic esophagitis, or chronic rhinosinusitis with nasal polyps, impact patients’ quality of life?
- What challenges do patients face in managing their type 2 inflammatory disease(s) on a daily basis?
- Describe type 2 inflammation. What diseases beyond those mentioned above can it be associated with?
- What causes this overactive inflammatory response? In your clinical practice, how often do you see patients with type 2 inflammation?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
3
Disability, Economic Toll of Multimorbidity Climb in Older Adults
4
October FDA Approvals Bring Advances Across 5 Specialties
5